Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

26. juni 2017 oppdatert av: Takeda

A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety and Efficacy of TAK-536, Amlodipine and Hydrochlorothiazide in Subjects With Essential Hypertension

The purpose of this study is to evaluate the safety of long-term administration of TAK-536, amlodipine (AML), and hydrochlorothiazide (HCTZ) in participants with essential hypertension.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The drug being tested in this study is called TAK-536TCH. TAK-536TCH is being tested to treat people who have essential hypertension. The study looked at effectiveness and long-term safety of TAK-536TCH in people who took TAK-536CCB in addition to standard care.

The study enrolled 341 patients. Participants received:

  • TAK-536CCB (as TAK-536/AML, 20 mg/5 mg) in run-in period,
  • TAK-536TCH (as TAK-536/ AML/HCTZ, 20 mg/5 mg/12.5 mg) in treatment period
  • TAK-536CCB and HCTZ 12.5 mg in treatment period

All participants were asked to take tablets at the same time each day throughout the study.

This multi-center trial was conducted in Japan. The overall time to participate in this study was 56 weeks (4 weeks run-in period and 52 weeks treatment period). Participants made multiple visits to the clinic during the study.

Studietype

Intervensjonell

Registrering (Faktiske)

341

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Japan
      • Choufu-shi, Japan
      • Kawasaki-shi, Japan
      • Koutou-ku, Japan
      • Morioka-shi, Japan
      • Sakaide-shi, Japan
      • Setagaya-ku, Japan
      • Shinagawa-ku, Japan
      • Shinjuku-ku, Japan
      • Tsukuba-shi, Japan
      • Uji-shi, Japan
      • Yaizu-shi, Japan
    • Aichi
      • Nagoya-shi, Aichi, Japan
    • Chiba
      • Chiba-shi, Chiba, Japan
    • Fukuoka
      • Itojima-shi, Fukuoka, Japan
    • Fukushima
      • Kouriyama-shi, Fukushima, Japan
    • Hokkaido
      • Sapporo-shi, Hokkaido, Japan
    • Hyougo
      • Amagasaki-shi, Hyougo, Japan
    • Ibaragi
      • Tsukuba-shi, Ibaragi, Japan
    • Iwate
      • Morioka-shi, Iwate, Japan
    • Kagawa
      • Sakaide-shi, Kagawa, Japan
      • Takamatsu-shi, Kagawa, Japan
    • Kanagawa
      • Kawasaki-shi, Kanagawa, Japan
    • Kyoto
      • Kyoto-shi, Kyoto, Japan
      • Uji-shi, Kyoto, Japan
    • Miyagi
      • Sendai-shi, Miyagi, Japan
    • Osaka
      • Hirakata-shi, Osaka, Japan
      • Osaka-shi, Osaka, Japan
      • Takatsuki-shi, Osaka, Japan
    • Saitama
      • Saitama-shi, Saitama, Japan
      • Tokorozawa-shi, Saitama, Japan
    • Shizuoka
      • Yaizu-shi, Shizuoka, Japan
    • Tokyo
      • Chiyoda-ku, Tokyo, Japan
      • Choufu-shi, Tokyo, Japan
      • Kodaira-shi, Tokyo, Japan
      • Koutou-ku, Tokyo, Japan
      • Setagaya-ku, Tokyo, Japan
      • Shinagawa-ku, Tokyo, Japan
      • Shinjuku-ku, Tokyo, Japan

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

20 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. In the opinion of the investigator or subinvestigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant signs and dates a written informed consent form prior to the initiation of any study procedures.
  3. The participant has essential hypertension.
  4. The participant has an office sitting systolic blood pressure (SBP) of <180 mmHg and office sitting diastolic blood pressure (DBP) of < 110 mmHg at the start of the run-in period (Week -4). Participants receiving combined therapy with a 3-drug antihypertensive within 4 weeks prior to the start of the run-in period is required to have an office sitting SBP of < 160 mmHg and an office sitting DBP of < 100 mmHg.

  5. The participant's office sitting blood pressure at Week -2 and at the end of the run-in period (Week 0) need to be either:

    • Participants without concurrent diabetes mellitus or chronic kidney disease (CKD)*: Sitting SBP of ≥ 140 mmHg or sitting DBP of ≥ 90 mmHg

    • Participants with concurrent diabetes mellitus or CKD*: Sitting SBP of ≥ 130 mmHg or sitting DBP of ≥ 80 mmHg.

      • Estimate glomerular filtration rate according to creatinine (eGFRcreat) of <60 mL/min/1.73 m^2, or urinary albumin (spot urine) of ≥30 μg/mL in laboratory tests performed at Week -2 of the run-in period, and diagnosed with CKD by the investigator or subinvestigator.
  6. The participant has an office sitting SBP of < 160 mmHg and office sitting DBP of < 100 mmHg at the end of the run-in period (Week 0).
  7. The participant is male or female, aged 20 years or older at the time of providing informed consent.
  8. The participant is an outpatient.
  9. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agree to use routinely adequate contraception from signing of informed consent through 1 month following the end of the study.

Exclusion Criteria:

  1. The participant has received any study drugs within 12 weeks prior to the start of the run-in period.
  2. The participant has participated in another clinical study or a post-marketing study within 30 days prior to the start of the run-in period.
  3. The participant is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g. spouse, parent, child, sibling), or may consent under duress.
  4. The participant requires taking prohibited concomitant drugs during the study.
  5. The participant has a history of hypersensitivity or allergies to TAK-536, AML, HCTZ, any thiazide diuretic or analog, any dihydropyridine drug, or any analog of TAK-536TCH.
  6. The participant is judged by the investigator or subinvestigator to be in danger of experiencing an excessive increase in blood pressure when changing or discontinuing premedication.
  7. The participant received combination therapy with antihypertensive drugs of the 3 ingredients contained in TAK-536TCH.
  8. The participant received combined therapy with antihypertensive drugs, including 4 or more components, within 4 weeks prior to the start of the run-in period.
  9. The participant has secondary or malignant hypertension.
  10. The participant has a difference of ≥ 20 mmHg between left and right arms in office sitting SBP at the start of the run-in period (Week -4).
  11. The participant has apparent white coat hypertension or exhibits a white coat effect.
  12. . The participant has a day-night reversed lifestyle, such as those working during the night.
  13. The participant has sleep apnea syndrome requiring treatment.

  14. The participant has any of the following cardiovascular diseases:

    • Cardiac disease: Myocardial infarction*, coronary arterial revascularization*, severe valvular disorder, atrial fibrillation, any of the following conditions requiring treatment: angina pectoris, congestive heart failure, arrhythmia
    • Cerebrovascular disorders: Cerebral infarction/cerebral hemorrhage*, transient ischemic attack*
    • Vascular disease: Peripheral artery disease with intermittent claudication, artery dissection, aneurysm
    • Advanced hypertensive retinopathy: With bleeding or exudate/papilledema** * Occurring or performed within 24 weeks of the start of the run-in period ** Observed within 24 weeks of the start of the run-in period
  15. The participant has a clinically apparent hepatic disorder (e.g., aspartate aminotransferase (AST) or alanine aminotransferase (ALT) at Week -2 of the run-in period ≥ 2.5 times the upper limit of normal (ULN).
  16. The participant has a clinically severe renal disorder (e.g., eGFRcreat in laboratory tests performed at Week -2 of run-in period < 30 mL/minute/1.73 m^2).

  17. The participant's body fluid sodium or potassium level is markedly low* or high*.

    *Based on normal ranges

  18. The participant has gout or a history of gout within 24 weeks of the start of the run-in period or has hyperuricemia requiring drug treatment.
  19. The participant has uncontrolled diabetes (e.g., HbA1c ≥ 7.4% in laboratory tests performed at Week -2 of the run-in period).
  20. The participant has a malignant tumor.
  21. If female, the participant is pregnant or lactating or before giving informed consent, intending to become pregnant or donate ova during or within 1 month after participating in the study.
  22. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to the run-in period.
  23. The participant who, in the opinion of the investigator or subinvestigator, is unsuitable for any other reason.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: TAK-536TCH

For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast.

For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg orally, once daily, before or after breakfast.
Legemiddel: TAK-536TCH tablet
TAK-536TCH tablets
Legemiddel: TAK-536CCB tablet
TAK-536CCB tablets
Legemiddel: HCTZ 12.5 mg tablet
HCTZ tablets

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Tidsramme: Baseline up to Week 52
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Baseline up to Week 52
Number of Participants With Markedly Abnormal Vital Signs Values
Tidsramme: Baseline up to Week 52
Vital signs included supine and standing systolic and diastolic blood pressure (SBP and DBP) respectively and office sitting pulse. Vital signs were considered abnormal if they were beyond the values defined in categories.
Baseline up to Week 52
Number of Participants With Treatment Emergent Adverse Event (TEAE) Related to Body Weight
Tidsramme: Baseline up to Week 52
Reported TEAE is categorized into investigations System Organ Class (SOC) related to body weight.
Baseline up to Week 52
Number of Participants With Treatment Emergent Adverse Event (TEAE) Related to Electrocardiogram (ECG)
Tidsramme: Baseline up to Week 52
Reported TEAE is categorized into cardiac disorders and investigations system organ class (SOC) related to ECG.
Baseline up to Week 52
Number of Participants With Markedly Abnormal Clinical Laboratory Tests
Tidsramme: Baseline up to Week 52
The number of participants with any markedly abnormal clinical laboratory test values collected throughout study. RBC = Red blood cells, ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transferase, LLN = lower limit of normal or lower reference limit, ULN = upper limit of normal or upper reference limit. Laboratory vallues were considered abnormal if they were beyond the values defined in categories.
Baseline up to Week 52

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change From Baseline in Office Trough Sitting Clinic Systolic and Diastolic Blood Pressure at Each Visit
Tidsramme: Baseline (End of Run-in Period, Week 0) and Weeks 12 (LOCF) and 52 (LOCF)
The change in office trough SBP and DBP measured at Weeks 12 last observation was carried forward (LOCF) and 52 (LOCF) relative to baseline. Sitting blood pressure was measured at least 3 times. Each measurement session ended once blood pressure was found stable at 2 consecutive measurements. The average of the last 2 measurements of office sitting blood pressure was used.
Baseline (End of Run-in Period, Week 0) and Weeks 12 (LOCF) and 52 (LOCF)
Change From Baseline in Home Sitting Clinic Systolic and Diastolic Blood Pressure at Each Visit
Tidsramme: Baseline (End of Run-in Period, Week 0), End of Week 12 and End of Treatment (Up to Week 52)
The change in home morning SPB and DBP measured at End of Week 12, End of Treatment (Up to Week 52) relative to baseline.
Baseline (End of Run-in Period, Week 0), End of Week 12 and End of Treatment (Up to Week 52)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Takeda

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. november 2014

Primær fullføring (Faktiske)

25. april 2016

Studiet fullført (Faktiske)

25. april 2016

Datoer for studieregistrering

Først innsendt

27. oktober 2014

Først innsendt som oppfylte QC-kriteriene

27. oktober 2014

Først lagt ut (Anslag)

29. oktober 2014

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. august 2017

Siste oppdatering sendt inn som oppfylte QC-kriteriene

26. juni 2017

Sist bekreftet

1. juni 2017

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • TAK-536TCH/OCT-001
  • U1111-1163-0169 (Registeridentifikator: WHO)
  • JapicCTI-142689 (Registeridentifikator: JapicCTI)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere